Investors
Business model
Our business is to build a pioneering biotech company, leveraging proprietary nanofiber-based drug delivery technology to develop innovative pharmaceutical products. Our approach integrates cutting-edge science with translational expertise to advance therapies from academic research through preclinical and clinical development, with a focus on oncology and surgical applications.
Cebiotex aims to establish strategic partnerships or licensing agreements with pharmaceutical companies capable of scaling and distributing our therapies globally. This model enables us to focus on innovation while ensuring broad clinical adoption.
We welcome collaboration opportunities with biotech innovators and pharmaceutical investors.
- Why invest in Cebiotex?
- Commitment to global impact: intellectual property portfolio that spans key international markets such as Europe, the US and Japan, supporting our ambition to bring transformative therapies to patients worldwide.
- Innovative technology platform for the local delivery of therapeutics: scalable through proprietary GMP-certified production ensuring efficiency and reproducibility, and versatile across different small molecules and wide range of therapeutic areas.
- Sound leadership team with extensive experience in biotech innovation, clinical development, and commercialization, backed by the strong strategic guidance and commitment of the Board.
- Targeted indications with high unmet medical need, particularly in pediatric and adult oncology. This focus increases the potential for regulatory incentives accelerating time to market.
- Tight collaborations with leading clinical research institutions enable us to understand patient needs and collaborate with clinicians and researchers to develop solutions that improve outcomes and quality of life.